Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/18/2024 | $288.00 | Mkt Outperform | JMP Securities | |
9/11/2024 | Buy → Neutral | H.C. Wainwright | ||
9/3/2024 | Overweight | Cantor Fitzgerald | ||
5/31/2024 | $70.00 | Overweight | Piper Sandler | |
5/1/2024 | $40.00 | Buy | Stifel | |
4/15/2024 | Outperform | William Blair | ||
3/7/2024 | $81.00 | Overweight | Morgan Stanley | |
2/15/2024 | $30.00 | Outperform | Wedbush |
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. "We are thrilled to welcome Aaron amid a transformational year for BeiGene as we became a top 15 global oncology innovator by revenue with sustained progress to profitability and one of the most prolific and innovative pipelines in our industry including a plan to have at least 10 new molecular entities this year. Aaron's financial leadership and impr
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)
SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)
8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
25-NSE - Galera Therapeutics, Inc. (0001563577) (Subject)
Arcellx (NASDAQ:ACLX) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 4 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $81.5, a high estimate of $87.00, and a low estimate of $70.00. A decline of 1.81% from the prior average price target
Canaccord Genuity analyst John Newman maintains Arcellx (NASDAQ:ACLX) with a Buy and maintains $85 price target.
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Arcellx, Inc. (0001786205) (Issuer)
4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)
JMP Securities initiated coverage of BeiGene with a rating of Mkt Outperform and set a new price target of $288.00
H.C. Wainwright downgraded Adicet Bio from Buy to Neutral
Cantor Fitzgerald initiated coverage of Arcellx with a rating of Overweight
4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed in third quarter of 2024 Company to pursue rheumatoid arthritis (RA) as second autoimmune indication for CLN-978 development CLN-619 combination therapy data presented at ASCO demonstrated objective responses in oncogenic driver mutation NSCLC, which is typically unresponsive to checkpoint inhibition Company appoints Mary Thistle to its Board of Directors CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported re
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reporte
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the "Board") has unanimously resolved to adopt a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the comp
Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus The trial will be conducted in multiple sites in Australia as well as other countries around the world CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today received Human Research Ethics Committee (HREC) approval in Australia to initiate its global Phase 1 clinical trial to evaluate CLN-978, its CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE). SLE af
CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today shared that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its CD19xCD3 bispecific T cell engager, CLN-978, for the treatment of systemic lupus erythematosus (SLE). "We are pleased to take the next step to advance our global study of CLN-978 in SLE in the U.S.," said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. "The Centers for Disease Control and Prevention (CDC) estimates SLE impacts more tha
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with zipalertinib who progressed on or after prior amivantamab treatment Enrollment of pivotal Phase 2b trial complete ahead of schedule CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today shared updated data in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutati